Skip to Main Content

Paper Details

CAMKV Is a Candidate Immunotherapeutic Target in <i>MYCN</i> Amplified Neuroblastoma.
Front Oncol
11
2020
CAMKV, KELLY, MYCN, MYCN Amplified Neuroblastoma, MYCN amplified cell lines, MYCN amplified neuroblastoma cell lines, MYCN amplified neuroblastomas, MYCN protein, NB-1643, NGP, RNA, calcium, calmodulin, calmodulin kinase, calmodulin kinase family members, differentially-expressed gene list, gene promoters, human, neuroblastoma, neuroblastoma tumors, patient
Author NameAffiliation
Pichai RamanDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Pichai RamanChildren's Hospital of Philadelphia
Pichai RamanDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Pichai RamanChildren's Hospital of Philadelphia
Komal S RathiDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Komal S RathiChildren's Hospital of Philadelphia
Komal S RathiDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Komal S RathiChildren's Hospital of Philadelphia
Daniel MartinezChildren's Hospital of Philadelphia
Daniel MartinezChildren's Hospital of Philadelphia
Kristopher R BosseDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Kristopher R BosseChildren's Hospital of Los Angeles
Maria V LaneDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
Lori S HartDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
John M MarisChildren's Hospital of Philadelphia
John M MarisDivision of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia
John M MarisChildren's Hospital of Philadelphia
  • 1 - 18

Datasets

Release 1.2